Xiangya Hospital of Central South University
Xiangya Hospital of Central South University
Changsha, Hunan, China36 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, gonadal disorder, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, squamous cell carcinoma, transitional cell carcinoma, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT04152499 | |
| A Study of ATG-201 in Adult Participants With Autoimmune Diseases | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, skin disorder, systemic lupus erythematosus, systemic sclerosis | Not yet recruiting | Phase 1 | 2026-09-21 | NCT07732309 | |
| Renal Oxygenation-Guided AKI Reduction Trial | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, acute kidney injury, kidney disorder, kidney failure, urinary system disorder | Not yet recruiting | Not applicable | 2026-09-14 | NCT07816640 | |
| Safety and Efficacy of Ventricular Irrigation for Ventriculitis | Infections, central nervous system disorder, central nervous system infectious disorder, nervous system disorder | Recruiting | Not applicable | 2026-09-10 | NCT06358209 | |
| A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE | Non-cystic Fibrosis Bronchiectasis | Active, not recruiting | Not stated | 2026-09-08 | NCT07245407 | |
| Clinical Study of Cizutamig in Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 1 | 2026-09-02 | NCT07215663 | |
| Pregnancy Salt Substitution Trial for Hypertensive Disorders of Pregnancy Prevention (PREG-Salt) | Hypertensive Disorders of Pregnancy | Recruiting | Not applicable | 2026-08-28 | NCT07294807 | |
| A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy | Cranial Nerve Injuries, Craniocerebral Trauma, cranial nerve neuropathy, eye disorder, glaucoma, injury, nervous system disorder, nervous system injury, ocular hypertension, open-angle glaucoma, optic nerve disorder, traumatic optic neuropathy | Recruiting | Phase 2 | 2026-08-24 | NCT07777861 | |
| Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis | Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, dermatitis, sebaceous gland disorder, seborrheic dermatitis, skin disorder | Not yet recruiting | Phase 3 | 2026-08-21 | NCT07683806 | |
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT06680921 | |
| Safety and Efficacy of Eculizumab in High-risk TA-TMA | Transplant-Associated Thrombotic Microangiopathy (TA-TMA) | Recruiting | Phase 2 | 2026-07-17 | NCT07707687 | |
| Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors | Healthy Allogeneic Hematopoietic Stem Cell Donor; Healthy Hematopoietic Stem Cell Donor | Recruiting | Phase 3 | 2026-07-15 | NCT07692841 | |
| Adaptive DBS for PD | Dyskinesias, Neurologic Manifestations, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not applicable | 2026-06-22 | NCT07635823 | |
| Zishen Yutai Pill for Patients With Recurrent Implantation Failure | Recurrent Implantation Failure | Not yet recruiting | Not applicable | 2026-06-11 | NCT07641088 | |
| Impact of Radiotherapy-Immunotherapy Timing in NSCLC Brain Metastases | Brain Metastasases; Non Small Cell Lung | Not yet recruiting | Not stated | 2026-06-10 | NCT07638709 | |
| Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Recruiting | Phase 3 | 2026-05-28 | NCT07390123 | |
| Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study) | Acute-On-Chronic Liver Failure, Digestive System Diseases, Hepatic Insufficiency, acute liver failure, liver disorder, liver failure | Active, not recruiting | Not stated | 2026-05-26 | NCT05129904 | |
| HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Warm Antibody Autoimmune Hemolytic Anemia | Active, not recruiting | Phase 2 / Phase 3 | 2026-05-18 | NCT05535933 | |
| Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure | Finerenone; HFpEF - Heart Failure With Preserved Ejection Fraction; TAVI(Transcatheter Aortic Valve Implantation) | Not yet recruiting | Phase 3 | 2026-05-08 | NCT07575672 | |
| HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management | cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-05-08 | NCT07402239 | |
| Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2026-04-23 | NCT06889688 | |
| Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis | Moderate to Severe Ulcerative Colitis | Active, not recruiting | Phase 2 | 2026-04-03 | NCT05486104 | |
| A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome | Primary Sjögren Syndrome | Not yet recruiting | Phase 2 | 2026-02-03 | NCT07375524 | |
| A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, systemic lupus erythematosus | Recruiting | Phase 1 | 2026-02-02 | NCT07331272 | |
| 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma | Disease Attributes, Disease Progression, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 3 | 2026-01-09 | NCT07328854 |